Talaris Therapeutics plans to dial back its research plans and restructure, the latest setback for a biotechnology company that’s been reeling since the death of a patient in a clinical trial last year.
In a Thursday statement, Talaris said it’s halting two of its three ongoing human trials following a strategic review. The two trials being stopped were evaluating a cell therapy meant to build tolerance to a donated kidney following a transplant.
